10x Genomics, INC Form 4 insider transactions

Director Shehnaaz Suliman reports acquisition of 8,649 shares of 10x Genomics Class A Common Stock through restricted stock units.

Mathai Mammen, a director at 10x Genomics, acquired 8,649 shares of Class A Common Stock through restricted stock units on June 11, 2024.

Serge Saxonov, CEO of 10x Genomics, reported the disposal of 425 shares of Class A Common Stock on May 29, 2024.

Justin J. McAnear, CFO of 10x Genomics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

10x Genomics CEO Serge Saxonov sold 4,877 shares of Class A Common Stock on May 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 4,087 shares of Class A Common Stock on May 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Serge Saxonov, CEO of 10x Genomics, filed a Form 4 detailing the acquisition of restricted stock units and changes in his beneficial ownership of Class A Common Stock.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, reports the acquisition of 71,083 restricted stock units.

Justin J. McAnear, CFO of 10x Genomics, reports the acquisition of restricted stock units (RSUs) representing a contingent right to receive Class A Common Stock.

Serge Saxonov, CEO of 10x Genomics, reports the transfer of Class A Common Stock to various trusts in a recent SEC filing.

10x Genomics CEO Serge Saxonov sold 4,660 shares of Class A Common Stock at an average price of $43.9959 on March 4, 2024.